Abstract
BACKGROUND: Aerosol and humidification therapy are used in long-term airway management of critically ill patients with a tracheostomy. The purpose of this study was to determine delivery efficiency of jet and mesh nebulizers combined with different humidification systems in a model of a spontaneously breathing tracheotomized adult with or without exhaled heated humidity.
METHODS: An in vitro model was constructed to simulate a spontaneously breathing adult (tidal volume, 400 mL; breathing frequency, 20 breaths/min; inspiratory-expiratory ratio, 1:2) with a tracheostomy using a teaching manikin attached to a test lung through a collecting filter (Vital Signs Respirgard II). Exhaled heat and humidity were simulated using a cascade humidifier set to deliver 37°C and >95% relative humidity. Albuterol sulfate (2.5 mg/3 mL) was administered with a jet nebulizer (AirLife Misty Max) operated at 10 L/min and a mesh nebulizer (Aeroneb Solo) using a heated pass-over humidifier, unheated large volume humidifier both at 40 L/min output and heat-and-moisture exchanger. Inhaled drug eluted from the filter was analyzed via spectrophotometry (276 nm).
RESULTS: Delivery efficiency of the jet nebulizer was less than that of the mesh nebulizer under all conditions (P < .05). Aerosol delivery with each nebulizer was greatest on room air and lowest when heated humidifiers with higher flows were used. Exhaled humidity decreased drug delivery up to 44%.
CONCLUSIONS: The jet nebulizer was less efficient than the mesh nebulizer in all conditions tested in this study. Aerosol deposition with each nebulizer was lowest with the heated humidifier with high flow. Exhaled humidity reduced inhaled dose of drug compared with a standard model with nonheated/nonhumidified exhalation. Further clinical research is warranted to understand the impact of exhaled humidity on aerosol drug delivery in spontaneously breathing patients with tracheostomy using different types of humidifiers.
Footnotes
- Correspondence: Arzu Ari PhD RRT PT CPFT FAARC, Department of Respiratory Therapy, Georgia State University, P.O. Box 4019, Georgia 30302-4019. E-mail: arzuari{at}hotmail.com.
This study was funded by the American Respiratory Care Foundation. Dr Ari has disclosed a relationship with Aerogen Ltd. Dr Fink has disclosed relationships with Aerogen, Bayer, Boerhinger Ingleheim, Dance Biopharm, Novartis, ONY, Parion, Aridis, and the World Health Organization. No company had input into the study design or execution. The other authors have disclosed no conflicts of interest.
- Copyright © 2016 by Daedalus Enterprises
